Molecularly Recognized Polymeric Soft Materials: Glucose-Responsive Hydrogels Enable Closed-Loop Insulin Delivery

Taylor & Francis Online International

Overview

This review reports advances in molecularly recognized polymeric soft materials, particularly glucose-responsive hydrogel systems. These hydrogels are fabricated into microneedle patches for continuous glucose control, integrating hypoxia-responsive vesicles triggered by enzymatic glucose oxidation or PBA-modified polymers within painless microneedles. This demonstrated rapid closed-loop insulin delivery in type 1 diabetic mouse models, marking a significant step towards clinical application.

In Depth

Background: Evolution of Diabetes Treatment and the Role of Smart Materials

Diabetes management, particularly blood glucose control in Type 1 diabetes, requires strict insulin administration to prevent complications. However, conventional insulin injections impose a significant burden on patients and make it difficult to respond to glucose fluctuations in real-time. In recent years, research into smart materials, especially bioresponsive polymeric hydrogels, has advanced, leading to expectations for self-regulating drug delivery systems, notably ‘closed-loop’ systems that release insulin in response to blood glucose levels.

Glucose-Responsive Hydrogel Microneedle Patch Technology

The review highlights innovations in molecularly recognized polymeric soft materials, specifically glucose-responsive hydrogel systems. These hydrogels are ingeniously fabricated into microneedle patches for continuous glucose control. The patch integrates two primary mechanisms: first, vesicles that release insulin in response to hypoxic conditions triggered by enzymatic glucose oxidation; and second, phenylboronic acid (PBA)-modified polymers incorporated within painless microneedles. PBA reversibly binds to glucose, changing the hydrogel’s swelling degree to control insulin release. This combination achieves a highly integrated system that ‘senses’ and ‘delivers’ insulin according to blood glucose levels.

Clinical Demonstration and Future Outlook

This glucose-responsive hydrogel microneedle patch demonstrated rapid and effective closed-loop insulin delivery in a Type 1 diabetic mouse model. This groundbreaking result means that insulin is automatically released when blood glucose levels rise, effectively maintaining glucose within a normal range. This capability addresses not only daytime insulin management but also glucose fluctuations during periods when the patient is unconscious, such as at night. This achievement holds the potential to significantly improve the quality of life for diabetes patients and reduce the risk of complications. Moving forward, clinical trials in humans are anticipated, aiming to establish this technology as an innovative tool in actual diabetes treatment, marking a significant step towards truly autonomous diabetes management systems.